Our current technical analysis of Inozyme Pharma (NASDAQ:INZY)
 | By Rifka Kats | Macroaxis Story |
Whilst many millenniums are getting more into healthcare space, it makes sense to break down Inozyme Pharma against current trends within the economy. As we have suggested previously, Inozyme Pharma is beginning its slide as investors shift to be more bearish due to the increased sector volatility. The returns on the market and returns on Inozyme Pharma appear slightly correlated for the last few months. Weak basic indicators of the company may also suggest signs of long term losses for Inozyme investors. Inozyme Pharma is scheduled to announce its earnings today.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
The firm's average rating is Strong Buy from 4 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Inozyme Pharma market sentiment investors' perception of the future value of Inozyme. Let us look at a few aspects of Inozyme technical analysis.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inozyme PharmaInc. Your research has to be compared to or analyzed against Inozyme PharmaInc's peers to derive any actionable benefits. When done correctly, Inozyme PharmaInc's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Inozyme PharmaInc.
Using predictive technical analysis, we can analyze different prices and returns patterns and diagnose historical swings to determine the real value of Inozyme PharmaInc. In general, sophisticated investors focus on analyzing Inozyme PharmaInc stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Inozyme PharmaInc's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Inozyme PharmaInc's intrinsic value. In addition to deriving basic predictive indicators for Inozyme PharmaInc, many experienced traders also check how macroeconomic factors affect Inozyme PharmaInc price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Inozyme PharmaInc's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Inozyme PharmaInc's Liquidity
Inozyme PharmaInc financial leverage refers to using borrowed capital as a funding source to finance Inozyme PharmaInc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Inozyme PharmaInc financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Inozyme PharmaInc's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Inozyme PharmaInc's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Inozyme PharmaInc's total debt and its cash.
Inozyme PharmaInc Gross Profit
Inozyme PharmaInc Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Inozyme PharmaInc previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Inozyme PharmaInc Gross Profit growth over the last 10 years. Please check Inozyme PharmaInc's gross profit and other fundamental indicators for more details.
Breaking down Inozyme PharmaInc Indicators
Inozyme Pharma has a beta of -0.7882. Let's try to break down what Inozyme's beta means in this case. The returns on MARKET and Inozyme Pharma are completely uncorrelated. The beta indicator helps investors understand whether Inozyme Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Inozyme deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Net Loss for the year was (22.49 M).
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Inozyme PharmaInc. Please refer to our Terms of Use for any information regarding our disclosure principles.